Telecare Provides Comparable Efficacy to Conventional Self-Monitored Blood Glucose in Patients with Type 2 Diabetes Titrating One Injection of Insulin Glulisine-the ELEONOR Study

被引:34
作者
Del Prato, Stefano [1 ]
Nicolucci, Antonio [2 ]
Lovagnini-Scher, Augusto C. [3 ]
Turco, Salvatore [4 ]
Leotta, Sergio [5 ]
Vespasiani, Giacomo [6 ]
机构
[1] Univ Pisa, Dept Endocrinol & Metab, Sect Diabet & Metab Dis, I-56124 Pisa, Italy
[2] Mario Negri Sud Consortium, Dept Clin Pharmacol & Epidemiol, Santa Maria Imbaro, Italy
[3] San Gerardo Hosp Monza, Ctr Diabet, Cusano Milanino, Italy
[4] Univ Naples Federico II, Dept Clin & Expt Med, Naples, Italy
[5] Sandro Pertini Hosp, Rome B, Italy
[6] Madonna del Soccorso Hosp, Diabetol & Metab Disorders Ctr, San Benedetto Tronto, Italy
关键词
BASAL-BOLUS REGIMEN; TO-TARGET TRIAL; GLYCEMIC CONTROL; THERAPY; GLARGINE; MANAGEMENT; DETEMIR; TELEMEDICINE; ADJUSTMENT; ALGORITHM;
D O I
10.1089/dia.2011.0163
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: We compared telecare and conventional self-monitored blood glucose (SMBG) programs for titrating the addition of one bolus injection of insulin glulisine in patients with type 2 diabetes uncontrolled on oral hypoglycemic agents for >= 3 months who were first titrated with basal insulin glargine. Methods: This randomized, multicenter, parallel-group study included 241 patients (mean screening glycosylated hemoglobin [HbA(1c)], 8.8% [73 mmol/mol]). In the run-in phase, any antidiabetes medication, except for metformin, was discontinued. Metformin was then up-titrated to 2 g/day (1 g twice daily) until study completion. Following run-in, all patients started glargine for 8-16 weeks, targeting fasting plasma glucose (FPG) <= 5.6 mmol/L using conventional SMBG. Patients with FPG <= 7 mmol/L added a glulisine dose at the meal with the highest postprandial plasma glucose excursion, titrated to target 2-h postprandial plasma glucose level < 7.8mmol/L using telecare or SMBG for 24 weeks. Patients with FPG > 7 mmol/L at week 16 were withdrawn from the study. Results: After glargine titration, 224 patients achieved FPG <= 7 mmol/L, without any difference between telecare and SBMG groups (mean +/- SD, 6.2 +/- 0.8 vs. 6.0 +/- 0.9 mmol/L, respectively). HbA(1c) levels were lower following titration and were similar for telecare and SMBG (7.9 +/- 0.9% vs. 7.8 +/- 0.9% [63 vs. 62 mmol/mol], respectively). Adding glulisine further reduced HbA(1c) in both groups (-0.7% vs. -0.7%); 45.2% and 54.8% (P = 0.14), respectively, of patients achieved HbA(1c) <= 7.0% (<= 53 mmol/mol). Weight change and hypoglycemia were similar between groups. Conclusions: Patients adding one dose of glulisine at the meal with the highest postprandial plasma glucose excursion to titrated basal glargine achieved comparable improvements in glycemic control irrespective of traditional or telecare blood glucose monitoring.
引用
收藏
页码:175 / 182
页数:8
相关论文
共 22 条
[1]   Adjust to target in type 2 diabetes - Comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine [J].
Bergenstal, Richard M. ;
Johnson, Mary ;
Powers, Margaret A. ;
Wynne, Alan ;
Vlajnic, Aleksandra ;
Hollander, Priscilla ;
Rendell, Marc .
DIABETES CARE, 2008, 31 (07) :1305-1310
[2]   Are there time and cost savings by using telemanagement for patients on intensified insulin therapy? A randomised, controlled trial [J].
Biermann, E ;
Dietrich, W ;
Rihl, J ;
Standl, E .
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, 2002, 69 (02) :137-146
[3]   Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study [J].
Blickle, J. -F. ;
Hancu, N. ;
Piletic, M. ;
Profozic, V. ;
Shestakova, M. ;
Dain, M. -P. ;
Jacqueminet, S. ;
Grimaldi, A. .
DIABETES OBESITY & METABOLISM, 2009, 11 (04) :379-386
[4]   Mobile communication using a mobile phone with a glucometer for glucose control in Type 2 patients with diabetes: as effective as an Internet-based glucose monitoring system [J].
Cho, Jae-Hyoung ;
Lee, Hye-Chung ;
Lim, Dong-Jun ;
Kwon, Hyuk-Sang ;
Yoon, Kun-Ho .
JOURNAL OF TELEMEDICINE AND TELECARE, 2009, 15 (02) :77-82
[5]  
Foley JE, 2010, VASC HEALTH RISK MAN, V6, P541
[6]   New technologies for chronic disease managment and control:: a systematic review [J].
Garcia-Lizana, Francisca ;
Sarría-Santamera, Antonio .
JOURNAL OF TELEMEDICINE AND TELECARE, 2007, 13 (02) :62-68
[7]   Telemedicine as a tool for intensive management of diabetes:: the DIABTel experience [J].
Gómez, EJ ;
Hernando, ME ;
García, A ;
Del Pozo, F ;
Cermeño, J ;
Corcoy, R ;
Brugués, E ;
De Leiva, A .
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, 2002, 69 (02) :163-177
[8]   A 52-Week, Multinational, Open-Label, Parallel-Group, Noninferiority, Treat-to-Target Trial Comparing Insulin Detemir with Insulin Glargine in a Basal-Bolus Regimen with Mealtime Insulin Aspart in Patients with Type 2 Diabetes [J].
Hollander, Priscilla ;
Cooper, John ;
Bregnhoj, Jesper ;
Pedersen, Claus Bang .
CLINICAL THERAPEUTICS, 2008, 30 (11) :1976-1987
[9]   Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes [J].
Holman, Rury R. ;
Farmer, Andrew J. ;
Davies, Melanie J. ;
Levy, Jonathan C. ;
Darbyshire, Julie L. ;
Keenan, Joanne F. ;
Paul, Sanjoy K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (18) :1736-1747
[10]   Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes [J].
Janka, HU ;
Kliebe-Frisch, C ;
Plewe, G ;
Schweitzer, MA ;
Riddle, MC ;
Yki-Jarvinen, H .
DIABETES CARE, 2005, 28 (02) :254-259